VISEN Pharma Schedules 22 April 2026 EGM to Ratify Exclusive Licence and Supply Agreements with Ascendis Units

Bulletin Express03-26

VISEN Pharmaceuticals has issued a proxy circular convening an extraordinary general meeting (EGM) for 10:00 a.m. on 22 April 2026 at Room 1701, 1788 Square, 1788 West Nanjing Road, Jing’an District, Shanghai. Shareholders will vote on three ordinary resolutions that collectively formalise the group’s collaboration framework with several Ascendis entities.

1. Exclusive Licence Framework Agreement • Counterparties: VISEN Pharmaceuticals and the ELA Ascendis Subsidiaries • Execution date: 26 March 2026 • Scope: Approval, confirmation and ratification of the agreement, the revised 2026 annual cap and future annual caps for transactions under the arrangement. • Board authorisation: Directors will be empowered to take all steps deemed necessary to implement the licence framework.

2. 1st Commercial Supply Framework Agreement • Counterparties: VISEN HK and Ascendis Pharma Endocrinology Division • Execution date: 26 March 2026 • Scope: Approval of the revised 2026 CSA annual cap and future annual caps related to commercial supply of products. • Board authorisation: Directors will be granted the same implementation powers as above.

3. Supplemental Agreement to the 2nd Commercial Supply Framework Agreement • Counterparties: VISEN HK and Ascendis Europe • Execution date: 26 March 2026 • Scope: Ratification of the supplemental agreement and revised 2nd CSFA annual caps. • Board authorisation: Identical implementation authority to the previous resolutions.

Shareholders may appoint multiple proxies; completed proxy forms must reach Computershare Hong Kong Investor Services Ltd. by 10:00 a.m. on 20 April 2026. Completion of a proxy does not preclude shareholders from attending and voting in person.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment